Operating Segments - Schedule of Adjusted EBITDA is Reconciled with the Consolidated Profit (Loss) Before Taxes (Details) - USD ($) $ in Thousands |
12 Months Ended | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|||||||||||||||||||||||
| Schedule of Adjusted EBITDA is Reconciled with the Consolidated Profit (Loss) Before Taxes [Abstract] | |||||||||||||||||||||||||
| Profit (loss) before taxes | $ 2,620,298 | $ 2,711,003 | $ (259,728) | ||||||||||||||||||||||
| Share of profit of equity-accounted investees, net of tax | (16,897) | (2,945) | (9,537) | ||||||||||||||||||||||
| Net finance expense | 1,556,276 | 1,669,763 | 1,353,405 | ||||||||||||||||||||||
| Depreciation and amortization | 2,308,520 | 2,189,547 | 2,149,066 | ||||||||||||||||||||||
| Antitrust agreements | [1] | 182,275 | 253,731 | 102,500 | |||||||||||||||||||||
| Donations and social programs | [2] | 1,806 | 22,467 | 18,166 | |||||||||||||||||||||
| Impairment of assets | [3] | 21,148 | 26,268 | ||||||||||||||||||||||
| Restructuring | [4] | 33,424 | 95,556 | 52,235 | |||||||||||||||||||||
| Fiscal payments and installments | [5] | 2,378 | 81,766 | ||||||||||||||||||||||
| Rio Grande do Sul claim | [6] | 19,313 | |||||||||||||||||||||||
| Extemporaneous litigation | [7] | 20,716 | 61,016 | ||||||||||||||||||||||
| Reversal of tax credits | [8] | 58,654 | |||||||||||||||||||||||
| Avian influenza | [9] | 17,092 | |||||||||||||||||||||||
| Tax assessment notice | [10] | 43,200 | |||||||||||||||||||||||
| Other operating income (expense), net | [11] | 41,161 | 32,000 | 25,510 | |||||||||||||||||||||
| Elimination | 1,325 | 2,583 | |||||||||||||||||||||||
| Total Adjusted EBITDA for operating segments | $ 6,831,397 | $ 7,193,196 | $ 3,460,468 | ||||||||||||||||||||||
| |||||||||||||||||||||||||